CpG-Activated Regulatory B-Cell Progenitors Alleviate Murine Graft-Versus-Host-Disease.
Bregs: regulatory B cells
CpG-proBs
allogeneic stem cell transplantation (allo-SCT)
cell therapy
fibrosis
graft-versus host disease
regulatory B-cell progenitors
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
06
10
2021
accepted:
21
03
2022
entrez:
28
4
2022
pubmed:
29
4
2022
medline:
30
4
2022
Statut:
epublish
Résumé
Development of Graft Versus Host Disease (GVHD) represents a major impediment in allogeneic hematopoietic stem cell transplantation (HSCT). The observation that the presence of bone marrow and circulating hematogones correlated with reduced GVHD risks prompted us to evaluate whether B-cell progenitors, which provide protection in various autoimmune disease models following activation with the TLR-9 agonist CpG (CpG-proBs), could likewise reduce this allogeneic disorder. In a murine model of GVHD that recapitulates an initial phase of acute GVHD followed by a phase of chronic sclerodermatous GVHD, we found that CpG-proBs, adoptively transferred during the initial phase of disease, reduced the diarrhea score and mostly prevented cutaneous fibrosis. Progenitors migrated to the draining lymph nodes and to the skin where they mainly differentiated into follicular B cells. CpG activation and IFN-γ expression were required for the protective effect, which resulted in reduced CD4
Identifiants
pubmed: 35479094
doi: 10.3389/fimmu.2022.790564
pmc: PMC9035844
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
790564Informations de copyright
Copyright © 2022 Agbogan, Gastineau, Tejerina, Karray and Zavala.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Infect Immun. 2015 May;83(5):1738-48
pubmed: 25712928
Blood. 2011 Feb 17;117(7):2275-83
pubmed: 21097674
Blood. 2013 Apr 18;121(16):3274-83
pubmed: 23422748
Blood. 2014 Jun 19;123(25):3988-98
pubmed: 24820310
Br J Haematol. 2009 Apr;145(1):107-14
pubmed: 19183190
PLoS One. 2014 Mar 12;9(3):e91492
pubmed: 24621606
J Immunol. 2006 Nov 15;177(10):7312-21
pubmed: 17082650
Immunol Lett. 2016 Feb;170:52-63
pubmed: 26772435
Int J Biochem Cell Biol. 2009 Aug-Sep;41(8-9):1708-18
pubmed: 19433312
Leuk Lymphoma. 2000 Jul;38(3-4):221-34
pubmed: 10830730
J Invest Dermatol. 2016 Feb;136(2):507-515
pubmed: 26824743
J Clin Invest. 2017 Jun 30;127(7):2452-2463
pubmed: 28665299
Biofactors. 2013 Nov-Dec;39(6):593-6
pubmed: 23893513
Biol Blood Marrow Transplant. 2018 Oct;24(10):1990-1996
pubmed: 29909151
J Immunol. 2012 Jul 1;189(1):464-74
pubmed: 22649199
Blood. 2015 Mar 12;125(11):1830-9
pubmed: 25605369
Sci Adv. 2020 Jul 29;6(31):eabb0806
pubmed: 32832688
Nat Commun. 2019 Jan 14;10(1):190
pubmed: 30643147
Blood. 2014 Sep 25;124(13):2034-45
pubmed: 25051962
Hum Immunol. 2019 Jun;80(6):393-399
pubmed: 30849450
Eur J Immunol. 2011 Nov;41(11):3351-60
pubmed: 21887788
Blood. 2005 Oct 15;106(8):2903-11
pubmed: 15972448
Oncoimmunology. 2017 Feb 6;6(3):e1284721
pubmed: 28405514
J Immunol. 2001 Dec 15;167(12):6834-40
pubmed: 11739500
Immunol Rev. 2013 Mar;252(1):146-55
pubmed: 23405902
J Immunol. 2013 Jul 1;191(1):488-99
pubmed: 23709681
Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):E2199-208
pubmed: 23716674
Blood Adv. 2019 Dec 23;3(24):4187-4201
pubmed: 31856270
J Vis Exp. 2016 Jan 25;(107):e53638
pubmed: 26863129
Front Immunol. 2019 Mar 20;10:522
pubmed: 30949175
Methods Mol Biol. 2016;1371:79-88
pubmed: 26530795
Immunity. 2015 Apr 21;42(4):607-12
pubmed: 25902480
Blood. 2016 Feb 4;127(5):646-57
pubmed: 26670634
J Allergy Clin Immunol. 2017 Jul;140(1):215-222
pubmed: 27865860
Biol Blood Marrow Transplant. 2012 Jun;18(6):968-73
pubmed: 22446015
Nat Commun. 2016 Jul 11;7:12134
pubmed: 27396388
Front Immunol. 2021 Mar 26;12:641013
pubmed: 33841422
J Cell Commun Signal. 2009 Dec;3(3-4):215-25
pubmed: 19844806
J Clin Invest. 2010 May;120(5):1479-93
pubmed: 20389017
Immunity. 2015 Jun 16;42(6):1005-19
pubmed: 26084021
Front Immunol. 2020 Nov 24;11:579776
pubmed: 33329550
Ann Hematol. 2015 Dec;94(12):2055-60
pubmed: 26336968
J Immunol. 2011 Dec 1;187(11):5720-32
pubmed: 22048769
Sci Immunol. 2017 Apr 7;2(10):
pubmed: 28738016
J Immunol. 2010 Feb 1;184(3):1526-35
pubmed: 20042577
FEBS J. 2007 Mar;274(5):1246-55
pubmed: 17298441
Blood. 2004 Nov 15;104(10):3294-301
pubmed: 15271801
Blood. 2018 May 3;131(18):2074-2085
pubmed: 29363542
Blood. 2013 Jan 31;121(5):840-8
pubmed: 23233661
Blood. 2009 Apr 16;113(16):3865-74
pubmed: 19168788
Blood. 2016 Sep 8;128(10):1346-61
pubmed: 27439912
Blood Adv. 2018 Sep 25;2(18):2307-2319
pubmed: 30228128
Blood. 2016 May 19;127(20):2489-97
pubmed: 26944544
Nat Commun. 2018 Nov 28;9(1):5037
pubmed: 30487586
Genes Dev. 2008 May 15;22(10):1276-312
pubmed: 18483217